Leading stem cell and exosome therapy research blog by Cell La Vie, Bangkok. Clinical insights, cost breakdowns, and regenerative treatment guides.
2026 Q3 update on allogeneic vs autologous MSC: head-to-head trial data, donor-age impact, 2026 manufacturing advances, when each is preferred, the cost picture, and FAQ for patients in Thailand and Asia-Pacific.
Read More »Osteoporosis after menopause affects millions of women. New 2026 research shows mesenchymal stem cells and exosomes can rebuild bone density safely. Here’s what patients need to know.
Read More »If you or someone you love is living with ALS (Amyotrophic Lateral Sclerosis), you already know the hardest part of the diagnosis: being told to wait. Wait for research. Wait for trials. Wait for something to change. But something is changing — and it’s happening faster than many people realize. Around the world, researchers are exploring a […]
Read More »Explore the latest 2026 research on stem cell therapy for dry Age-Related Macular Degeneration (AMD). Learn how RPE cell transplantation and clinical trials offer new hope for restoring vision. Consult Cell La Vie.
Read More »New 2026 research reveals UC-MSC exosomes combined with low-intensity pulsed ultrasound and curcumin-hydrogel systems achieve remarkable burn wound healing — including MRSA-infected wounds — through autophagy regulation, anti-scarring mechanisms, and immunomodulation. Five landmark papers reviewed.
Read More »2026 patient guide to MSC therapy for Alzheimer’s disease: how it differs from lecanemab and donanemab, who is a candidate, what outcomes to expect, the 6 active clinical trials including NCT06775964 and the first MSC + antibody drug combination trial.
Read More »Is Stem Cell Therapy Legal and Safe in Thailand? For international patients considering regenerative treatments, traveling abroad for stem cell therapy brings both immense hope and important practical questions. As medical tourism in Southeast Asia expands, Thailand—specifically Bangkok—has established itself as a leading global center for advanced cellular therapies. However, prospective patients from the United […]
Read More »Zimislecel (VX-880) is the first stem cell-derived islet therapy to reach the FDA, and the September 2025 NEJM paper showed 12 of 12 patients achieving insulin independence. Here’s what it means for T1D patients in 2026, who qualifies, and what options exist in Thailand now.
Read More »5 MSC and exosome trials for psoriasis have reported completion; three 2026 mechanistic studies reveal novel Ang1/Tie2 angiogenesis mechanisms, engineered exosome-nanoparticle platforms, and culture medium optimization for psoriasis-specific MSC potency.
Read More »A 2026 meta-analysis of 7 randomized trials confirms intradiscal MSC injections reduce chronic back pain and disability significantly. Meanwhile, bioengineered exosome therapies are redefining what cell-free disc regeneration looks like.
Read More »CRISPR-edited MSCs, iPSC-derived cells, combinatorial cell therapy, and exosome-based approaches are transforming PAD/CLI treatment. Six landmark 2026 papers and five active clinical trials reviewed for clinicians and researchers.
Read More »